Fulcrum Therapeutics
FULC
126 hedge funds and large institutions have $570M invested in Fulcrum Therapeutics in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 11 closing their positions.
2,404% more call options, than puts
Call options by funds: $30.4M | Put options by funds: $1.21M
227% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 11
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
35% more capital invested
Capital invested by funds: $421M → $570M (+$149M)
25% more funds holding
Funds holding: 101 → 126 (+25)
14% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 29
3.3% less ownership
Funds ownership: 100.78% → 97.48% (-3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$10.2M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.29M |
| 3 |
Millennium Management
New York
|
+$4.11M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$3.8M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$23.8M |
| 2 |
Morgan Stanley
New York
|
-$11.4M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.7M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.6M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.57M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LGM
126
Logos Global Management
San Francisco,
California
| – | -$10.7M | -1,200,000 | Closed |
|
|
CAM
127
ClariVest Asset Management
San Diego,
California
| – | -$722K | -106,977 | Closed |
|
|
6CM
128
683 Capital Management
New York
| – | -$316K | -46,778 | Closed |
|
|
MA
129
MYDA Advisors
Woodmere,
New York
| – | -$198K | -29,370 | Closed |
|
|
SI
130
Sofinnova Investments
Menlo Park,
California
| – | -$193K | -28,600 | Closed |
|
131
Bank of New York Mellon
New York
| – | -$134K | -19,831 | Closed |
|
|
MFS
132
Mirabella Financial Services
London,
United Kingdom
| – | -$114K | -16,914 | Closed |
|
|
LA
133
LM Advisors
San Diego,
California
| – | -$109K | -16,132 | Closed |
|
134
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$97.8K | -14,200 | Closed |
|
|
BFM
135
Boothbay Fund Management
New York
| – | -$79.2K | -11,730 | Closed |
|
|
SPA
136
Sherbrooke Park Advisers
White Plains,
New York
| – | -$78.9K | -11,684 | Closed |
|
FULC Hedge Fund Activity: Q1 2024 in Review
126 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q1 2024, worth a combined $570M — up 35% from $421M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new FULC positions and 11 closed out — a net gain of 25 holders — while 33 added to existing stakes and 29 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $10.2M. The largest seller was Suvretta Capital Management, cutting an estimated $23.8M.
- 126 institutional investors held Fulcrum Therapeutics (FULC) as of Q1 2024, up from 101 in Q4 2023.
- Funds reported $570M of Fulcrum Therapeutics stock for Q1 2024, up 35% quarter-over-quarter.
- 36 funds opened new Fulcrum Therapeutics positions in Q1 2024 and 11 closed out, a net change of +25 holders.
- The largest Fulcrum Therapeutics buyer in Q1 2024 was MPM BioImpact, an estimated $10.2M added.
- The largest Fulcrum Therapeutics seller in Q1 2024 was Suvretta Capital Management, an estimated $23.8M sold.
Based on aggregated 13F filings for Q1 2024.